TY - JOUR
T1 - Tms-eeg research to elucidate the pathophysiological neural bases in patients with schizophrenia
T2 - A systematic review
AU - Li, Xuemei
AU - Honda, Shiori
AU - Nakajima, Shinichiro
AU - Wada, Masataka
AU - Yoshida, Kazunari
AU - Daskalakis, Zafiris J.
AU - Mimura, Masaru
AU - Noda, Yoshihiro
N1 - Funding Information:
Acknowledgments: Y.N. has received a Grant-in-Aid for Young Scientists and Grant-in-Aid for Scientific Research (B) from the Japan Society for the Promotion of Science (JSPS), research grants from Japan Agency for Medical Research and Development (AMED), investigator-initiated clinical study grants from TEIJIN PHARMA LIMITED and Inter Reha Co., Ltd. Y.N. also receives research grants from Japan Health Foundation, Meiji Yasuda Mental Health Foundation, Mitsui Life Social Welfare Foundation, Takeda Science Foundation, SENSHIN Medical Research Foundation, Health Science Center Foundation, Mochida Memorial Foundation for Medical and Pharmaceutical Research, Taiju Life Social Welfare Foundation, and Daiichi Sankyo Scholarship Donation Program. Y.N. has received speaker’s honoraria from Dainippon Sumitomo Pharma, MOCHIDA PHARMACEUTICAL CO., LTD., and Yoshitomiyakuhin Corporation within the past three years. Y.N. also receives equipment-in-kind support for an investigator-initiated study from Magventure Inc, Inter Reha Co., Ltd., BrainBox Ltd., and Miyuki Giken Co., Ltd. S.N. has received a Grant-in-Aid for Young Scientists A and Grants-in-Aid for Scientific Research B and C from JSPS, and research grants from Japan Research Foundation for Clinical Pharmacology, Naito Foundation, Takeda Science Foundation, Uehara Memorial Foundation, and Daiichi Sankyo Scholarship Donation Program within the past three years. S.N. has also received research support, manuscript fees, or speaker’s honoraria from Dainippon Sumitomo Pharma, Meiji-Seika Pharma, Otsuka Pharmaceutical, Shionogi, and Yoshitomi Yakuhin within the past three years. Z.J.D has received research support from the Ontario Mental Health (OMH) Foundation, the CIHR, the Brain and Behaviour Research Foundation (Formerly NARSAD), and the Temerty family and Grant family through the CAMH Foundation and the Campbell Institute. In the last 3 years, Z.J.D has received research and equipment in-kind support for an investigator-initiated study through Brainsway Inc and Magventure Inc. His work was supported by the Ontario Mental Health Foundation (OMHF), the Canadian Institutes of Health Research (CIHR), the National Institutes of Mental Health and the Temerty Family and Grant Family and through the Centre for Addiction and Mental Health (CAMH) Foundation and the Campbell Institute. M.M. received grants and/or speaker’s honoraria from Asahi Kasei Pharma, Astellas Pharma, Daiichi Sankyo, Sumitomo Dainippon Pharma, Eisai, Eli Lilly, Fuji Film RI Pharma, Janssen Pharmaceutical, Kracie, Meiji-Seika Pharma, Mochida Pharmaceutical, Merck Sharp and Dohme, Novartis Pharma, Ono Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Shionogi, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, and Yoshitomi Yakuhin. All other authors declare that they have no conflicts of interest.
Funding Information:
Y.N. has received a Grant-in-Aid for Young Scientists and Grant-in-Aid for Scientific Research (B) from the Japan Society for the Promotion of Science (JSPS), research grants from Japan Agency for Medical Research and Development (AMED), investigator-initiated clinical study grants from TEIJIN PHARMA LIMITED and Inter Reha Co., Ltd. Y.N. also receives research grants from Japan Health Foundation, Meiji Yasuda Mental Health Foundation, Mitsui Life Social Welfare Foundation, Takeda Science Foundation, SENSHIN Medical Research Foundation, Health Science Center Foundation, Mochida Memorial Foundation for Medical and Pharmaceutical Research, Taiju Life Social Welfare Foundation, and Daiichi Sankyo Scholarship Donation Program. Y.N. has received speaker’s honoraria from Dainippon Sumitomo Pharma, MOCHIDA PHARMACEUTICAL CO., LTD., and Yoshitomiyakuhin Corporation within the past three years. Y.N. also receives equipment-in-kind support for an investigator-initiated study from Magventure Inc, Inter Reha Co., Ltd., BrainBox Ltd., and Miyuki Giken Co., Ltd. S.N. has received a Grant-in-Aid for Young Scientists A and Grants-in-Aid for Scientific Research B and C from JSPS, and research grants from Japan Research Foundation for Clinical Pharmacology, Naito Foundation, Takeda Science Foundation, Uehara Memorial Foundation, and Daiichi Sankyo Scholarship Donation Program within the past three years. S.N. has also received research support, manuscript fees, or speaker’s honoraria from Dainippon Sumitomo Pharma, Meiji-Seika Pharma, Otsuka Pharmaceutical, Shionogi, and Yoshitomi Yakuhin within the past three years. Z.J.D has received research support from the Ontario Mental Health (OMH) Foundation, the CIHR, the Brain and Behaviour Research Foundation (Formerly NARSAD), and the Temerty family and Grant family through the CAMH Foundation and the Campbell Institute. In the last 3 years, Z.J.D has received research and equipment in-kind support for an investigator-initiated study through Brainsway Inc and Magventure Inc. His work was supported by the Ontario Mental Health Foundation (OMHF), the Canadian Institutes of Health Research (CIHR), the National Institutes of Mental Health and the Temerty Family and Grant Family and through the Centre for Addiction and Mental Health (CAMH) Foundation and the Campbell Institute. M.M. received grants and/or speaker’s honoraria from Asahi Kasei Pharma, Astellas Pharma, Daiichi Sankyo, Sumitomo Dainippon Pharma, Eisai, Eli Lilly, Fuji Film RI Pharma, Janssen Pharmaceutical, Kracie, Meiji-Seika Pharma, Mochida Pharmaceutical, Merck Sharp and Dohme, Novartis Pharma, Ono Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Shionogi, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, and Yoshitomi Yakuhin. All other authors declare that they have no conflicts of interest.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/5
Y1 - 2021/5
N2 - Schizophrenia (SCZ) is a serious mental disorder, and its pathogenesis is complex. Recently, the glutamate hypothesis and the excitatory/inhibitory (E/I) imbalance hypothesis have been proposed as new pathological hypotheses for SCZ. Combined transcranial magnetic stimulation (TMS) and electroencephalography (EEG) is a non-invasive novel method that enables us to investigate the cortical activity in humans, and this modality is a suitable approach to evaluate these hypotheses. In this study, we systematically reviewed TMS-EEG studies that investigated the cortical dysfunction of SCZ to examine the emerging hypotheses for SCZ. The following search terms were set in this systematic review: (TMS or ‘transcranial magnetic stimulation’) and (EEG or electroencephalog*) and (schizophrenia). We inspected the articles written in English that examined humans and were pub-lished by March 2020 via MEDLINE, Embase, PsycINFO, and PubMed. The initial search generated 379 studies, and 14 articles were finally identified. The current review noted that patients with SCZ demonstrated the E/I deficits in the prefrontal cortex, whose dysfunctions were also associated with cognitive impairment and clinical severity. Moreover, TMS-induced gamma activity in the prefrontal cortex was related to positive symptoms, while theta/delta band activities were associated with negative symptoms in SCZ. Thus, this systematic review discusses aspects of the pathophysiological neural basis of SCZ that are not explained by the traditional dopamine hypothesis exclusively, based on the findings of previous TMS-EEG research, mainly in terms of the E/I imbalance hypothesis. In conclusion, TMS-EEG neurophysiology can be applied to establish objective biomarkers for better diagnosis as well as to develop new therapeutic strategies for patients with SCZ.
AB - Schizophrenia (SCZ) is a serious mental disorder, and its pathogenesis is complex. Recently, the glutamate hypothesis and the excitatory/inhibitory (E/I) imbalance hypothesis have been proposed as new pathological hypotheses for SCZ. Combined transcranial magnetic stimulation (TMS) and electroencephalography (EEG) is a non-invasive novel method that enables us to investigate the cortical activity in humans, and this modality is a suitable approach to evaluate these hypotheses. In this study, we systematically reviewed TMS-EEG studies that investigated the cortical dysfunction of SCZ to examine the emerging hypotheses for SCZ. The following search terms were set in this systematic review: (TMS or ‘transcranial magnetic stimulation’) and (EEG or electroencephalog*) and (schizophrenia). We inspected the articles written in English that examined humans and were pub-lished by March 2020 via MEDLINE, Embase, PsycINFO, and PubMed. The initial search generated 379 studies, and 14 articles were finally identified. The current review noted that patients with SCZ demonstrated the E/I deficits in the prefrontal cortex, whose dysfunctions were also associated with cognitive impairment and clinical severity. Moreover, TMS-induced gamma activity in the prefrontal cortex was related to positive symptoms, while theta/delta band activities were associated with negative symptoms in SCZ. Thus, this systematic review discusses aspects of the pathophysiological neural basis of SCZ that are not explained by the traditional dopamine hypothesis exclusively, based on the findings of previous TMS-EEG research, mainly in terms of the E/I imbalance hypothesis. In conclusion, TMS-EEG neurophysiology can be applied to establish objective biomarkers for better diagnosis as well as to develop new therapeutic strategies for patients with SCZ.
KW - Cortical excitation
KW - Cortical inhibition
KW - Electroencephalography
KW - Schizophrenia
KW - TMS-evoked potentials
KW - Transcranial magnetic stimulation
UR - http://www.scopus.com/inward/record.url?scp=85106862859&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106862859&partnerID=8YFLogxK
U2 - 10.3390/jpm11050388
DO - 10.3390/jpm11050388
M3 - Review article
AN - SCOPUS:85106862859
SN - 2075-4426
VL - 11
JO - Journal of Personalized Medicine
JF - Journal of Personalized Medicine
IS - 5
M1 - 388
ER -